Background
High LDL cholesterol, often called “bad cholesterol,” is a major driver of atherosclerotic cardiovascular disease, including heart attack and stroke. One of the most important advances in lipid-lowering therapy has been the discovery that proprotein convertase subtilisin/kexin type 9, or PCSK9, plays a key role in regulating LDL receptors on liver cells. When PCSK9 promotes degradation of LDL receptors, fewer receptors remain available to clear LDL cholesterol from the bloodstream.
At present, approved PCSK9-lowering therapies are injectable monoclonal antibodies or siRNA-based treatments. These therapies can be highly effective, but injections may limit convenience, access, or long-term adherence for some patients. For that reason, an effective oral small-molecule PCSK9 inhibitor could represent an important new treatment option. Laroprovstat, also known as AZD0780, is an investigational oral small molecule designed to bind the C-terminal domain of PCSK9 and interfere with its harmful effect on LDL receptor recycling.
This report summarizes preclinical findings and the results of a randomized, single-blind, placebo-controlled phase 1 trial evaluating laroprovstat in people with elevated LDL cholesterol who had not yet received lipid-lowering treatment, as well as in a separate dose-escalation study in healthy participants.
How Laroprovstat Works
Unlike the currently available PCSK9 antibodies, laroprovstat does not directly block the PCSK9-LDL receptor binding site. Instead, it stabilizes the C-terminal domain of PCSK9. This appears to prevent PCSK9 from shuttling LDL receptors toward lysosomal degradation inside the cell. In practical terms, that means more LDL receptors remain on the surface of liver cells, where they can remove more LDL cholesterol from the blood.
This mechanism is notable because it supports an oral small-molecule approach to a target that has previously been difficult to inhibit with tablets. The preclinical work showed that laroprovstat increased LDL receptor expression and lowered LDL cholesterol in mice engineered to express human PCSK9.
Study Design
The clinical development program included two main parts. First, safety, tolerability, and pharmacokinetic properties were examined in healthy participants with LDL-C between 70 and 190 mg/dL after single ascending doses of laroprovstat. Pharmacokinetics refers to how the body absorbs, distributes, metabolizes, and eliminates a drug.
Second, laroprovstat was evaluated in participants with LDL-C between 100 and 190 mg/dL who first completed a 3-week run-in period with rosuvastatin 20 mg daily. After that run-in, participants received either laroprovstat 1 mg or 30 mg once daily, or placebo, for 28 days. Rosuvastatin is a potent statin widely used to reduce cholesterol production by the liver. Using it as a background therapy allowed investigators to examine whether laroprovstat could provide additional LDL-C lowering on top of standard statin treatment.
This phase 1 study was not designed to prove long-term cardiovascular benefit. Rather, it focused on early evidence of safety, dosing behavior, and lipid-lowering activity, which are essential first steps before larger phase 2 and phase 3 trials.
Key Pharmacokinetic Findings
Laroprovstat showed dose-proportional pharmacokinetics, meaning exposure increased in a predictable way as the dose increased. Its half-life was approximately 40 hours, which is consistent with once-daily dosing. This is important for patient adherence, because oral drugs with daily schedules are usually easier to take than medications requiring more frequent dosing.
Another useful finding was that food had no clinically meaningful effect on exposure. When laroprovstat was taken with a high-fat meal versus in the fasting state, the observed changes in overall exposure and peak concentration were small and not considered clinically important. In practical terms, this suggests laroprovstat may eventually be suitable to take with or without food, which could make real-world use simpler.
Safety and Tolerability
Laroprovstat was generally well tolerated in this early study. No safety findings of concern were reported. That is encouraging, especially for a first-in-class oral PCSK9 inhibitor, because early development must establish that the compound can be administered safely before moving into larger and longer studies.
As with all phase 1 studies, the sample size is limited, so uncommon side effects or rare safety issues may not be detected yet. Longer trials in broader patient populations will be needed to better define the safety profile, including whether there are any clinically meaningful liver, muscle, kidney, or metabolic effects when the drug is used alone or together with other lipid-lowering therapies.
Effect on LDL Cholesterol
The most clinically relevant result from the study was the LDL-C reduction seen in participants with hypercholesterolemia after rosuvastatin pretreatment. Compared with baseline after the statin run-in, laroprovstat 1 mg reduced LDL-C by 29%, and laroprovstat 30 mg reduced LDL-C by 51%.
When laroprovstat was combined with rosuvastatin, the total LDL-C reduction was approximately 70% with the 1 mg dose and about 80% with the 30 mg dose. This is a substantial lipid-lowering effect. In clinical practice, reductions of this magnitude are often considered highly meaningful, especially for patients who remain above target despite statin therapy alone or who need very aggressive LDL lowering because of very high cardiovascular risk.
These results also suggest that laroprovstat may work well as add-on therapy rather than as a replacement for statins. Statins reduce cholesterol synthesis, while PCSK9 inhibition preserves LDL receptors. Combining these mechanisms can produce a larger overall effect than either approach alone.
Why This Matters
The search for an oral PCSK9 inhibitor has been important for years. Injectable PCSK9-targeting therapies have already shown that lowering PCSK9 can markedly reduce LDL cholesterol, but injections may not suit every patient. An oral small-molecule option could lower treatment burden, broaden access in some settings, and potentially improve adherence over time.
If future trials confirm the efficacy and safety seen here, laroprovstat could become a practical addition to the lipid-lowering toolbox. It may be especially relevant for patients with severe hypercholesterolemia, heterozygous familial hypercholesterolemia, or those who do not reach guideline LDL-C targets with statins alone.
It is important to note, however, that LDL lowering is only one step on the path to improved cardiovascular outcomes. Large outcome trials are needed to show whether reducing LDL cholesterol with laroprovstat translates into fewer heart attacks, strokes, and cardiovascular deaths.
Limitations of the Study
Because this was a phase 1 trial, several limitations should be kept in mind. The study involved a relatively small number of participants and short follow-up. The trial was not designed to detect long-term safety problems or cardiovascular outcome benefits. Also, the lipid-lowering findings were measured over weeks, not months or years.
Another limitation is that the study population was selected and carefully monitored, so the results may not fully reflect what happens in routine clinical practice. Differences in age, comorbidities, background therapies, and adherence could affect real-world performance.
Despite these limitations, the study provides an important proof of concept that an oral small-molecule PCSK9 inhibitor can lower LDL cholesterol effectively in humans.
Clinical Perspective
For clinicians, laroprovstat represents a promising new mechanism in lipid management. The findings support further development, especially in patients already receiving statins who still need more LDL-C lowering. If later studies confirm benefit, laroprovstat could eventually complement existing options such as statins, ezetimibe, bempedoic acid, and injectable PCSK9 therapies.
For patients, the key message is that better cholesterol control may soon become easier to achieve with an oral medicine designed to target a pathway previously accessible mainly through injections. That said, this is still early-stage research, and laroprovstat is not yet an approved treatment.
Conclusion
In this randomized phase 1 study, laroprovstat, an investigational oral small-molecule PCSK9 inhibitor, was well tolerated, showed favorable pharmacokinetics, and produced meaningful LDL cholesterol reductions when added to rosuvastatin. In treatment-naive participants with hypercholesterolemia, the combination of rosuvastatin 20 mg and laroprovstat 30 mg led to an approximately 80% reduction in LDL-C.
These findings support continued clinical development of laroprovstat as a potential first oral small-molecule PCSK9 inhibitor. Larger and longer studies will be needed to confirm safety, determine the best dosing strategy, and establish whether the drug improves cardiovascular outcomes in patients with hypercholesterolemia.
